



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/048,072
Filing Date	January 25, 2002
First Named Inventor	Franchini, Genoveffa
Group Art Unit	1648
Examiner Name	Parkin, Jeffrey

Sheet 1 of 3

Attorney Docket No: 1662.018US1

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
	US-2006/0094006A1	05/04/2006	Franchini, G. , et al.	05/01/2003
	US-5,593,972	01/14/1997	Weiner, D. B., et al.	09/21/1993
	US-5,766,598	06/16/1998	Paoletti, E. , et al.	09/07/1994
	US-5,817,637	10/06/1998	Weiner, D. B., et al.	01/13/1997
	US-5,863,542	01/26/1999	Paoletti, E. , et al.	04/05/1995
	US-7,094,408	08/22/2006	Franchini, G. , et al.	04/30/2001

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T ²
	WO-01/82964A1	11/08/2001	Franchini, G. , et al.	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		"#1 Data As Treatment / #2 HIV Antibody Breakthrough in Transgenic Mice Could Prove Boon to Vaccine", TAGLine 6(4), (1999), 11 pgs.	
		"Annual Report of the Treatment Action Group", (2001), 6 pgs.	
		"Application Serial No. 10/513,257 (Atty Ref 1662.013US1) Response filed 3-10-2008 to Non-Final Office Action mailed 12-10-2007", 15 pgs.	
		"Application Serial No. 10/513,257 (Atty Ref 1662.013US1), Non-Final Office Action mailed 12-10-2007", 11 pgs.	
		"Application Serial No. 10/513,257 (Atty. Ref. 1662.013US1), Final Office Action mailed in 08-01-2007", 15 pgs.	
		"How Vaccines Prevent Diseases", CDC - Vaccines and Immunizations, [online]. [retrieved 2008-2-26]. Retrieved from the Internet: http://www.cdc.gov/vaccines/vac-gen/howvpd.htm , 6 pgs.	
		"International search Report for corresponding PCT Application No. PCT/US03/13737", (Attorney Docket No. 1662.013WO1), (November 2, 2004), 2 pgs.	
		New Fusion Inhibitor AMD-3100 Begins Phase II", PRNewswire, www.natap.org/1999/june/61299.html , (05/27/1999), 3pgs.	
		"NIAID HIV Vaccine Trials Update", News from NIAID, (October 10, 1993), 5 pgs.	
		SMASH: Small Molecule NMR Conference (Small Molecules Are Still Hot)", Argonne Guest House, Argonne National Laboratory, Argonne IL (outside Chicago, IL), (1999), 4 pgs.	
		AMARA, R. R., "Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine", Science, Vol. 292, (April 6, 2001), 69-74	

EXAMINER

DATE CONSIDERED

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/048,072
Filing Date	January 25, 2002
First Named Inventor	Franchini, Genoveffa
Group Art Unit	1648
Examiner Name	Parkin, Jeffrey

Sheet 2 of 3

Attorney Docket No: 1662.018US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BENSON, J., et al., "Recombinant Vaccine-Induced Protection Against the Highly Pathogenic Simian Immunodeficiency Virus SIV _{mac251} : Dependence on Route of Challenge Exposure", <u>Journal of Virology</u> , 72(5), (1998),4170-4182	
		BEREGER, E., et al., "Reconsidering targeted toxins to eliminate HIV infection: you gotta have HAART", <u>Proc.Natl. Acad. Sci. USA</u> Vol. 95, (1998),11511-11513	
		HANKE, T., et al., "DNA multi-CTL epitope vaccines for HIV and <i>Plasmodium falciparum</i> : immunogenicity in mice", <u>Vaccine</u> , 16 (4), (1998),426-435	
		HANKE, T., "Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime", <u>Vaccine</u> , 16(5), (1998),439-445	
		HARRINGTON, M. , et al., "Hit HIV-1 hard, but only when necessary", <u>The Lancet</u> , (2000),355:2147-2152	
		KENT, S. J., "Enhanced T-Cell Immunogenicity and Protective Efficacy of a Human Immunodeficiency Virus Type 1 Vaccine Regimen Consisting of Consecutive Priming with DNA and Boosting with Recombinant Fowlpox Virus", <u>Journal of Virology</u> , 72(12), (Dec., 1998),10180-10188	
		KIEPIELA, P., et al., "CD8 ⁺ T-cell responses to different HIV proteins have discordant associations with viral load.", <u>Nat Med.</u> , 13(1), (Jan., 2007),46-53	
		KILBY, J M., "Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry", <u>Nat Med</u> Vol 4 (11), (Abstract Only), (1998),1302-1307	
		KIM, J. , et al., "Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV.", <u>J. interferon and Cytokine Res.</u> Vol. 19, (1999),77-84	
		MARTINEZ-PICADO, J. , et al., "Fitness Cost of Escape Mutations in p24 Gag in Association with Control of Human Immunodeficiency Virus Type 1", <u>Journal of Virology</u> , 80(7), (2006),3617-3623	
		MASCOLA, J. , et al., "Potent and Synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12", <u>J. Virol</u> Vol. 71 (10), (1997),7198-7206	
		OKUDA, K. , "DNA Vaccination Followed by Macromolecular Multicomponent Peptide Vaccination Against HIV-1 Induces Strong Antigen-Specific Immunity", <u>Vaccine</u> , 15(10), (1997),1049-1056	
		RAMSHAW, I. A., "The Prime-Boost Strategy: Exciting Prospects for Improved Vaccination", <u>Immunology Today</u> , 21(4), (2000),163-165	
		TRKOLA, A. , et al., "Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies.", <u>Nat Med.</u> , 11(6), (Jun., 2005),615-22	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1448)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached



Substitute for form 1449A/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Complete if Known

Application Number	10/048,072
Filing Date	January 25, 2002
First Named Inventor	Franchini, Genoveffa
Group Art Unit	1648
Examiner Name	Parkin, Jeffrey

Sheet 3 of 3

Attorney Docket No: 1662.018US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (In CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-Issue number(s), publisher, city and/or country where published.	T ²
		VON GEGERFELT, A. S., et al., "Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization.", J Virol., 81(4), (Feb., 2007), 1972-9	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached